Agenda

Avoid common pitfalls in early preclinical development for women's health therapeutics by generating early data that translates - strengthening asset credibility with investors, partners, and regulators. Many assets stall before clinical validation not because of weak science, but because preclinical models fail to capture sex-specific biology and produce reliable signals. Strengthen translatability through sex-specific models, more rigorous toxicology design, and biologically representative testing to reduce downstream failure risk and progress assets more confidently toward clinical validation, regulatory alignment, and commercial partnership.